Use of specimen mammography-guided FNA (fine-needle aspirates) for flow cytometric multiple marker analysis and immunophenotyping in breast cancer

Communications in Clinical Cytometry

Volumn 42, Issue 3, 2000, Pages 165-173

  Stomper, Paul C ^a   Budnick, Rose Marie ^a   Stewart, Carleton C ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Fine needle aspiration; Flow cytometry; Immunophenotyping; Mammographically detected breast lesions; Multiple marker analysis

Indexed keywords

CYTOKERATIN; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; ONCOGENE NEU; POLYPLOIDY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; BIOPSY, NEEDLE; BREAST; BREAST NEOPLASMS; CARCINOMA; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; DIPLOIDY; DNA; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; KERATINS; MAMMOGRAPHY; MIDDLE AGED; PILOT PROJECTS; RECEPTOR, ERBB-2; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR MARKERS, BIOLOGICAL;

EID: 0034659439     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0320(20000615)42:3<165::AID-CYTO2>3.0.CO;2-7     Document Type: Article

References (56)

1. Stomper PC, Stewart CC, Penetrante RB, Nava MER, Tsangaris TN. Flow cytometric DNA analysis of excised breast lesions: use of fresh tissue needle aspirates obtained under guidance with mammography of the specimen. Radiology 1992;185:415-422.
2. Stomper PC, DeBloom Jr II, Levine E, Budnick RM, Stewart CC. Flow cytometric DNA analysis of invasive carcinomas detected by screening mammography: use of specimen mammography-guided fine-needle aspirates. Clin Cancer Res 1998;4:1789-1795.
3. Stomper PC, Nava MER, Budnick RM, Stewart CC. Specimen mammography-guided fine-needle aspirates of mammographically normal fatty and dense benign tissue: analysis of cell number and type. Breast Cancer Res Treat 1997;45:135-139.
4. Stomper PC, DeBloom Jr II, Budnick RM, Stewart CC. Flow cytometric DNA analyses of benign lesions detected by screening mammography. Clin Cancer Res 1998;4:1543-1547.
5. Baer MR, Stewart CC, Lawrence D, Arthur DC, Mrozek K, Strout MP, Davey FR, Shiffer CA, Bloomfield CD. Acute myeloid leukemia with 11q23 translocations: myelomonocytic immunophenotype by multiparameter flow cytometry. Leukemia 1998;12:317-325.
6. Sood R, Stewart CC, Aplan PD, Murai H, Ward PD, Barcos M, Baer MR. Neutropenia associated with T-cell large granular lymphocyte leukemia: long term response to cyclosporine therapy despite persistence of abnormal cells. Blood 1998;91:3371-3378.
7. Wetzler M, Bernstein SH, Baumann H, Fries KM, Stewart CC, Blumenson L, Baer MR, Herzig GP, Bloomfield CD, Slack JL. Expression and function of the megakaryocyte growth and development factor receptor in acute myeloid leukemia blasts. Leuk Lymph 1998;30:415-431.
8. Stewart CC. Clinical applications of multiparameter flow cytometry. In: McArthur JR, Lee SH, Wong JE, Ong YW, editors. Haematology, 1996, Education Programme of the 26th Congress of the International Society of Haematology, 1996, Singapore, p 335-346.
9. Hedley DW, Friedlander ML, Taylor IW. Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance. Cytometry 1985;6:327-333.
10. Kallioniemi OP. Comparison of fresh and paraffin-embedded tissue as starting material for DNA flow cytometry and evaluation of intratumor heterogeneity. Cytometry 1988;9:164-169.
11. Kute TE, Gregory B, Galleshaw J, Hopkins M, Buss D, Case D. How reproducible are flow cytometry data from paraffin-embedded blocks? Cytometry 1988;9:494-498.
12. Ottesen GL, Christensen IJ, Larsen JK, Christiansen J, Hansen B, Andersen JA. DNA analysis of in situ ductal carcinoma of the breast via flow cytometry. Cytometry 1995;22:168-176.
13. Brotherick I, Shenton BK, Cowan WK, Angus B, Horne CH, Higgs MJ, Lennard TW. The relationship between flow-cytometric and immunohistochemically detected c-erbB-2 expression, grade and DNA ploidy in breast cancer (abstract). Cancer Immunol Immunother 1995;41:137-145.
14. Leers MP, Theunissen PH, Ramaekers FC, Schulte B. Multi-parameter flow cytometric analysis with detection of the Ki67-Ag in paraffin embedded mammary carcinomas (abstract). Cytometry 1997;27:283-289.
15. Brotherick I, Browell DA, Shenton BK, Egan M, Cunliffe WJ, Webb LA, Lunt LG, Young JR, Higgs MJ. The effect of 3-week tamoxifen treatment on oestrogen receptor levels in primary breast tumours: a flow cytometric study (abstract). Br J Cancer 1998;77:1657-1660.
16. McCormick SR, Peters AA, Schrauth JB. Flow cytometric DNA analysis with cytokeratin gating of formalin-fixed deparaffinized breast cancer nuclei. Am J Clin Pathol 1998;110:227-237.
17. Brotherick I, Shenton BK, Cowan WK, Angus B, Horne CH, Higgs MJ, Lennard TW. p53 expression measured by flow cytometry. A comparison of three monoclonal antibodies and the relationship with grade and DNA ploidy in breast cancer. Cancer Immunol Immunother 1995;41:146-150.
18. Kopans DB, Lindfors KK, McCarthy KA, Meyer JE. Spring hookwire breast lesion localizer: use with rigid-compression mammographic systems. Radiology 1985;157:537-538.
19. Stewart CC, Stewart SJ. Titering antibodies. In: Robinson JP, Darzynkiewicz Z, Dean P, Dressier L, Rabinovitch P, Stewart C, Tanke H, Wheeless L, editors. Current protocols in cytometry. New York: John Wiley & Sons; 1997. p 4.1.1-4.1.13.
20. Stomper PC, Nava MER, Budnick RM, Stewart CC. Specimen mammography-guided fine-needle aspiration of clinically occult benign and malignant lesions: analysis of cell type and number. Invest Radiol 1997;32:277-281.
21. Page DL, Anderson TJ. Diagnostic histopathology of the breast. New York: Churchill Livingstone; 1987. p 137-145.
22. Page DL, Vander Zwaag R, Rogers LW, Williams LT, Walker WE, Hartmann WH. Relation between component parts of fibrocystic disease complex and breast cancer. J Natl Cancer Inst 1978;61:1055-1063.
23. Fleiss JL. Statistical methods for rates and proportions, 2nd edition. New York: John Wiley & Sons; 1981. p 20-27.
24. Ljung BM, Chew K, Deng G, Matsumura K, Waldman F, Smith H. Fine needle aspiration techniques for the characterization of breast cancers. Cancer 1994;74:1000-1005.
25. Fuhr JE, Kattine AA, Nelson HS Jr. Evaluation of in vivo breast fine needle aspirates by flow cytometry: an efficacy study. J Natl Cancer Inst 1992;84:1272-1276.
26. Masood S. Use of monoclonal antibody for assessment of estrogen receptor content in fine-needle aspiration biopsy specimen from patients with breast cancer. Arch Pathol Lab Med 1989;113:26-30.
27. Frigo B, Pilotti S, Zurrida S, Ermellino L, Manzari A, Rilke F. Analysis of estrogen and progesterone receptors on preoperative fine-needle aspirates. Breast Cancer Res Treat 1995;33:179-184.
28. Gorczyca W, Tuziak T, Kram A, Melamed MR, Darzynkiewicz Z. Detection of apoptosis-associated DNA strand breaks in fine-needle aspiration biopsies by in situ end labeling of fragmented DNA. Cytometry 1994;15:169-175.
29. Lundy J, Lozowski M, Mishriki Y. Monoclonal antibody B72.3 as a diagnostic adjunct in fine needle aspirates of breast masses. Ann Surg 1986;203:399-402.
30. Glogovac JK, Porter PL, Banker DE, Rabinovitch PS. Cytokeratin labeling of breast cancer cells extracted from paraffin-embedded tissue for bivariate flow cytometric analysis. Cytometry 1996;24:260-267.
31. Brockhoff G, Fleischmann S, Meier A, Wachs FP, Hofstaedter F, Knuechel R. Use of a mechanical dissociation device to improve standardization of flow cytometric cytokeratin DNA measurements of colon carcinomas. Cytometry 1999;38:184-191.
32. Haung ZJ, Haugland RP, You WM. Phallotoxin and actin binding assay by fluorescence enhancement. Anal Biochem 1992;200:199-204.
33. Shankey TV, Rabinovitch PS, Bagwell B, Bauer KD, Duque RE, Hedley DW, Mayall BH, Wheeless L, Cox C. Guidelines for implementation of clinical DNA cytometry. Cytometry 1993;14:472-477.
34. Dickson RB, Paik S. Regulation of proliferation and differentiation of normal and malignant breast: new factors and neu paradoxes. Breast 1993;2:83.
35. Liu ET. Oncogenes, breast cancer and chemoprevention. J Cell Biochem 1993;17G(Suppl):161-166.
36. Hubbard AL, Doris CP, Thompson AM, Chetty U, Anderson TJ. Critical determination of the frequency of c-erB-2 amplification in breast cancer. Br J Cancer 1993;70:-434-439.
37. Lodato RF, Maguire HC Jr, Greene MI, Weiner DB, Livolsi VA. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Mod Pathol 1990;3:449-454.
38. van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R. neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988;319:1239-1245.
39. Fabian CJ, Zalles C, Kamel S, McKittrick R, Moore WP, Zeiger S, Simon C, Kimler B, Cramer A, Garcia F, Jewell W. Biomarker and cytologic abnormalities in women at high and low risk for breast cancer. J Cell Biochem 1993;17G:153-160.
40. Allred DC, Berardo MD, Prosser J, O'Connell P. Biologic and genetic features of in situ breast cancer. In: Silverstein MJ, editor. Ductal carcinoma in situ of the breast. Baltimore: Williams & Wilkins; 1997. p 40-41.
41. Ravdin PM, Chamness GC. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecule markers. Gene 1995;159:19-27.
42. Tetu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer: the influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994;73:2359-2365.
43. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L, et al. HER-2/neu in node negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992;10:599-605.
44. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R, et al. Prognostic importance of c-erbB-2 expression in breast cancer: International [Ludwig] Breast Cancer Study Group. J Clin Oncol 1992;10:1049-1056.
45. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R, et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993;53:4960-4970.
46. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts [published erratum appears in Cancer Res 1999;59:2020]. Cancer Res 1998;58:2825-2831.
47. Dublin EA, Barnes DM, Wang DY, King RJ, Levison DA. TGf alpha and TGF beta expression in mammary carcinoma. J Pathol 1993;170:15-22.
48. Mizukami Y, Nonomura A, Yamada T, Kurumaya H, Hayashi M, Koyasaki N, Taniya T, Noguchi M, Nakamura S, Matsubara F. Immunohistochemical demonstration of growth factors. TGF-alpha, TGF-beta, IGF-I and neu oncogene product in benign and malignant human breast tissues. Anticancer Res 1990;10:1115-1126.
49. Murray PA, Barrett-Lee P, Travers M, Luqmani Y, Powles T, Coombes RC. The prognostic significance of transforming growth factors in human breast cancer. Br J Cancer 1999;67:1408-1412.
50. Massague J. Epidermal growth factor-like transforming growth factor. J Biol Chem 1983;258:13606-13613.
51. Derynck R. Transforming growth factor a. Cell 1988;54:593-595.
52. Todaro GJ, Rose TM, Spooner CE, Shoyab M, Plowman GD. Cellular and viral ligands that interact with the EGF receptor. Semin Cancer Biol 1990;1:257-263.
53. Liscia DS, Merlo G, Ciardiello F, Kim N, Smith GH, Callahan R, Salomon DS. Transforming growth factor-a messenger RNA localization in the developing adult rat and human mammary gland by in situ hybridization. Dev Biol 1990;140:123-131.
54. Hedley DW, Clark GM, Cornelisse CJ, Killander D, Kute T, Merkel D. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Cytometry 1993;14:482-485.
55. Wenger CR, Beardslee S, Owens MA, Pounds G, Oldaker T, Vendely P, Pandian MR, Harrington D, Clark GM, McGuire WL. DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat 1993;28:9-20.
56. Vogel VG. Primary prevention of breast cancer In: Bland KI. Copeland EM III, editors. The breast, 2nd edition. Philadelphia: W.B. Saunders; 1991. p 362-369.